261 related articles for article (PubMed ID: 27582078)
1. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Moehler M; Gepfner-Tuma I; Maderer A; Thuss-Patience PC; Ruessel J; Hegewisch-Becker S; Wilke H; Al-Batran SE; Rafiyan MR; Weißinger F; Schmoll HJ; Kullmann F; von Weikersthal LF; Siveke JT; Weusmann J; Kanzler S; Schimanski CC; Otte M; Schollenberger L; Koenig J; Galle PR
BMC Cancer; 2016 Aug; 16(1):699. PubMed ID: 27582078
[TBL] [Abstract][Full Text] [Related]
2. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
[TBL] [Abstract][Full Text] [Related]
3. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
11. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
Klempner SJ; Maron SB; Chase L; Lomnicki S; Wainberg ZA; Catenacci DVT
Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Mukherjee S; Fountzilas C; Boland PM; Gosain R; Attwood K; Tan W; Khushalani N; Iyer R
Target Oncol; 2020 Feb; 15(1):85-92. PubMed ID: 31802410
[TBL] [Abstract][Full Text] [Related]
13. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
15. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Tsuji Y; Satoh T; Tsuji A; Muro K; Yoshida M; Nishina T; Nagase M; Komatsu Y; Kato T; Miyata Y; Mizutani N; Hashigaki S; Lechuga MJ; Denda T
Cancer Sci; 2012 Aug; 103(8):1502-7. PubMed ID: 22537162
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
17. A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
Liu X; Guo W; Zhang W; Yin J; Zhang J; Zhu X; Liu T; Chen Z; Wang B; Chang J; Lv F; Hong X; Wang H; Wang J; Zhao X; Wu X; Li J
BMC Cancer; 2017 Mar; 17(1):188. PubMed ID: 28288572
[TBL] [Abstract][Full Text] [Related]
18. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
20. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
